MAO inhibitors: Risks, benefits, and lore

@article{Wimbiscus2010MAOIR,
  title={MAO inhibitors: Risks, benefits, and lore},
  author={Molly Wimbiscus and Olga Kostenko and Donald Malone},
  journal={Cleveland Clinic Journal of Medicine},
  year={2010},
  volume={77},
  pages={859 - 882}
}
Monoamine oxidase (MAO) inhibitors were the first antidepressants introduced, but their use has dwindled because of their reported side effects, their food and drug interactions, and the introduction of other classes of agents. However, interest in MAO inhibitors is reviving. Here, we discuss their use, risks, and benefits in clinical medicine. Monoamine oxidase inhibitors were the first antidepressants introduced. Interest in their use is reviving. 

Tables from this paper

Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
TLDR
A better understanding of the foods and drugs that can cause adverse reactions, as well as knowledge of newer MAOIs with mechanisms of action and delivery methods that reduce these risks, may help clinicians to consider the use of these medications, when appropriate, in their patients with depression.
The role of monoamine oxidase inhibitors in depression treatment guidelines.
  • M. Thase
  • Psychology
    The Journal of clinical psychiatry
  • 2012
TLDR
A transdermal formulation of selegiline limits the need for dietary restrictions and has fewer side effects than many more widely used antidepressants, giving clinicians another option in their armamentarium for treating depression.
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
TLDR
This review revisits monoamine oxidase inhibitors and their potential in the treatment of human diseases, such as anxiety, depression, mood and personality disorders, and pain and introduces current ideas and developments.
From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors
TLDR
The authors review the relevance of MAO isoforms to disease, and they also outline current research and development efforts in this class of drugs, including newer multipotent compounds.
Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression
TLDR
Recent progress in RIMAs toward the treatment of treatment-resistant depression is discussed, with the new class of reversible monoamine oxidase inhibitors (RIMAs) having shown efficacy in depression, with safety and tolerability comparable to SSRIs.
Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination.
  • J. Israel
  • Psychology
    The primary care companion for CNS disorders
  • 2015
This report reviews the medical literature on combining stimulants with monoamine oxidase inhibitors. A case is also presented documenting successful treatment of major depressive disorder and
Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression
This paper reviews the discovery and history of the use of irreversible monoamine oxidase (MAO) inhibitors (MAOIs) such as phenelzine, tranylcypromine and isocarboxazid, as well as the second
Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells
TLDR
The potential role of MAOA inhibitors (MAOAIs) in relation to the androgen receptor (AR) pathway and resistance to antiandrogen treatment in prostate cancer is investigated.
Practical guide for prescribing MAOIs: debunking myths and removing barriers
TLDR
This article is intended to serve as a guide for clinicians who are not particularly familiar with MAO inhibitors to help these clinicians competently integrate these agents into clinical practice when appropriate.
“Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine
TLDR
An editorial to address the discrepancy between the published literature and the view of experienced practitioners contrasted with the reality of the near-total lack of use of MAOIs, and to encourage doctors to consider these drugs earlier in the illness-course of patients, to illuminate issues that are perceived as major hurdles.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Revisiting monoamine oxidase inhibitors.
  • K. Krishnan
  • Medicine
    The Journal of clinical psychiatry
  • 2007
TLDR
The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.
The Role of Monoamine Oxidase Inhibitors in Current Psychiatric Practice
TLDR
Clinicians must continue to familiarize themselves with the properties of and indications for prescribing MAOIs and identify symptom presentations more likely to respond to these medications.
Adverse Reactions to Monoamine Oxidase Inhibitors. Part I. A Comparative Study
TLDR
More side effects occurred on phenelzine, but these tended not to lead to drug discontinuation more often than with tranylcypromine, nor were they accounted for by differences in age, sex, diagnosis, or duration of treatment.
Pharmacokinetics of monoamine oxidase inhibitors.
TLDR
This review summarizes the existing pharmacokinetic literature on tranylcypromine, phenelzine, moclobemide, and selegiline and predicts that these drugs and others like them promise to become increasingly important in modern psychopharmacologic practice.
Tyramine and Irreversible Monoamine Oxidase Inhibitors in Clinical Practice
  • A. J. Cooper
  • Medicine, Chemistry
    British Journal of Psychiatry
  • 1989
TLDR
Second-generation MAOIs which are selective for monoamine oxidase-A and B are now being synthesised and may eliminate the eventuality of hypertension without special dietary precautions.
Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors
TLDR
Clinicians should familiarize themselves with the properties and indications for the new generation of MAOIs and it is possible that STS may demonstrate benefit in MDD with atypical features or MDD resistant to other antidepressants.
Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
  • M. Thase
  • Biology
    The Journal of clinical psychiatry
  • 2006
TLDR
The holy grail of this search for a better MAOI has been identification of a drug that did not require a special diet, has a tolerability and ease-of-use profile comparable to the selective serotonin reuptake inhibitors (SSRIs), and is as effective as tranylcypromine or phenelzine.
Monoamine Oxidase Inhibitors, Tyramine, and Cheese
TLDR
Marked potentiation of the pressor effects of tyramine hydrochloride, given orally and intravenously, was demonstrated in patients receiving a monoamine oxidase (MAO) inhibitor, and one of the hazards of treatment with MAO inhibitors is emphasized.
...
1
2
3
4
5
...